BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

NTHI upcoming catalysts

Neonc Technologies, Inc.: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 0 FDA event(s). Subscribe to NTHI (.ics).

Drugs: Perillyl alcohol, NEO100

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Neonc Technologies, Inc. NTHINCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaGlioblastoma Multiformeactive not recruiting49
2026-12-30 est.P2Neonc Technologies, Inc. NTHINCT05023018 NEO100 and High-Grade MeningiomaResidual, Progressive or Recurrent Grade II or III Meningiomarecruiting30

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.